To analyze the clinical characteristics of a serous retinopathy associated with mitogen-activated protein kinase kinase ( MEK ) inhibition with binimetinib treatment for metastatic cutaneous melanoma ( CM ) and uveal melanoma ( UM ) , and to determine possible pathogenetic mechanisms that may lead to this retinopathy .